OBJECTIVE: Cyclin D1 and FADD (Fas-associated protein with death domain) regulate the cell cycle and apoptosis, respectively, and are located on chromosome 11q13, which is frequently amplified in head and neck squamous cell carcinoma (HNSCC). This study evaluates these proteins as predictors of clinical outcomes for HNSCC. STUDY DESIGN: Historical cohort study. SETTING: Academic tertiary care center. SUBJECTS: Two hundred twenty-two patients with upper aerodigestive HNSCC. RESULTS: Patients with tumors that were strongly positive for cyclin D1 and FADD had reduced overall (OS; P = .003 and P < .001), disease-specific (DSS; P = .039 and P < .001), and disease-free (DFS; P = .026 and P < .001) survival, respectively. Together, the 2 markers effectively stratified OS (P < .001), DSS (P < .001), and DFS (P = .002). Strong FADD staining correlated with greater alcohol consumption and varied significantly with primary tumor site: 56% of hypopharynx tumors expressed high levels of FADD but only 7% of glottis tumors. Using Cox regression analysis, FADD and N stage were significant independent predictors of DSS and DFS, whereas cyclin D1, FADD, and N stage were independently significant for OS. CONCLUSION: Cyclin D1 and FADD may have utility as predictors of long-term outcomes for patients with HNSCC. Further study is needed to determine if these proteins predict response to different treatment approaches or assist in selecting patients for multimodality therapy.
OBJECTIVE:Cyclin D1 and FADD (Fas-associated protein with death domain) regulate the cell cycle and apoptosis, respectively, and are located on chromosome 11q13, which is frequently amplified in head and neck squamous cell carcinoma (HNSCC). This study evaluates these proteins as predictors of clinical outcomes for HNSCC. STUDY DESIGN: Historical cohort study. SETTING: Academic tertiary care center. SUBJECTS: Two hundred twenty-two patients with upper aerodigestive HNSCC. RESULTS:Patients with tumors that were strongly positive for cyclin D1 and FADD had reduced overall (OS; P = .003 and P < .001), disease-specific (DSS; P = .039 and P < .001), and disease-free (DFS; P = .026 and P < .001) survival, respectively. Together, the 2 markers effectively stratified OS (P < .001), DSS (P < .001), and DFS (P = .002). Strong FADD staining correlated with greater alcohol consumption and varied significantly with primary tumor site: 56% of hypopharynx tumors expressed high levels of FADD but only 7% of glottis tumors. Using Cox regression analysis, FADD and N stage were significant independent predictors of DSS and DFS, whereas cyclin D1, FADD, and N stage were independently significant for OS. CONCLUSION:Cyclin D1 and FADD may have utility as predictors of long-term outcomes for patients with HNSCC. Further study is needed to determine if these proteins predict response to different treatment approaches or assist in selecting patients for multimodality therapy.
Authors: Brittany M Bowman; Katrina A Sebolt; Benjamin A Hoff; Jennifer L Boes; Danette L Daniels; Kevin A Heist; Craig J Galbán; Rajiv M Patel; Jianke Zhang; David G Beer; Brian D Ross; Alnawaz Rehemtulla; Stefanie Galbán Journal: Sci Signal Date: 2015-01-27 Impact factor: 8.192
Authors: Mark J Jameson; Linnea E Taniguchi; Kyle K VanKoevering; Menachem M Stuart; Christian R Francom; Rolando E Mendez; Andrew D Beckler; Hans T Carlson; Christopher Y Thomas; Ashraf A Khalil Journal: J Oral Pathol Med Date: 2012-10-26 Impact factor: 4.253
Authors: Rui Jun Lin; Tarinee Lubpairee; Kelly Y Liu; Donald W Anderson; Scott Durham; Catherine F Poh Journal: J Otolaryngol Head Neck Surg Date: 2013-03-19
Authors: Brenen W Papenberg; James Ingles; Si Gao; Jun Feng; Jessica L Allen; Steven M Markwell; Erik T Interval; Phillip A Montague; Sijin Wen; Scott A Weed Journal: Cancer Genet Date: 2021-05-28